CDC42 and melanoma: In conclusion, while WNT5A‐deficient melanoma cells exhibit reduced Cdc42 signaling and invasion, we also identified a counteracting response to this reduction in invasion in BRAF wild‐type and BRAFV600 mutated melanoma cells treated with a BRAF inhibitor.